NASDAQ:BNTX BioNTech (BNTX) Stock Price, News & Analysis $86.56 -0.30 (-0.35%) As of 11:05 AM Eastern This is a fair market value price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About BioNTech Stock (NASDAQ:BNTX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get BioNTech alerts:Sign Up Key Stats Today's Range$85.00▼$86.5650-Day Range$86.86▼$116.5752-Week Range$79.52▼$124.00Volume367,874 shsAverage Volume1.10 million shsMarket Capitalization$21.89 billionP/E RatioN/ADividend YieldN/APrice Target$125.80Consensus RatingModerate Buy Company Overview BioNTech SE is a biotechnology company headquartered in Mainz, Germany, focused on developing medicines and vaccines based on messenger RNA and other immunotherapy technologies. The company’s research programs address cancer, infectious diseases, and other serious medical conditions. BioNTech’s oncology portfolio includes individualized and off-the-shelf cancer immunotherapies, including mRNA-based treatments, cell therapies, antibody-based therapies, and immune-modulating approaches. Its infectious-disease activities include vaccine programs developed through proprietary platforms and collaborations. In collaboration with Pfizer, BioNTech developed Comirnaty, an mRNA-based COVID-19 vaccine. The vaccine has been distributed internationally, giving BioNTech a global commercial presence through partnerships and regulatory approvals in multiple geographies. The company was founded in 2008 by Uğur Şahin, Özlem Türeci, and Christoph Huber; Şahin serves as chief executive officer and Türeci serves as chief medical officer.AI Generated. May Contain Errors. Read More BioNTech Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks87th Percentile Overall ScoreBNTX MarketRank™: 4.36254206575 of 5 starsBioNTech scored higher than 87% of companies evaluated by MarketBeat, and ranked 152nd out of 907 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.3 / 5Analyst RatingModerate Buy Consensus RatingBioNTech has received a consensus rating of Moderate Buy. The company's average rating score is 2.68, and is based on 1 strong buy rating, 12 buy ratings, 5 hold ratings, and 1 sell rating.Upside PotentialBioNTech has a consensus price target of $125.80, representing about 47.4% upside from its current price of $85.37.Amount of Analyst CoverageBioNTech has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about BioNTech's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for BioNTech are expected to grow in the coming year, from ($6.62) to ($5.30) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BioNTech is -10.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BioNTech is -10.99, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioNTech has a P/B Ratio of 0.88. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about BioNTech's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.11% of the float of BioNTech has been sold short.Short Interest Ratio / Days to CoverBioNTech has a short interest ratio ("days to cover") of 2.06, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BioNTech has recently decreased by 9.00%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioNTech does not currently pay a dividend.Dividend GrowthBioNTech does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment0.01 News SentimentBioNTech has a news sentiment score of 0.01. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.60 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 19 news articles for BioNTech this week, compared to 8 articles on an average week.Search InterestOnly 8 people have searched for BNTX on MarketBeat in the last 30 days. This is a decrease of -20% compared to the previous 30 days.MarketBeat Follows5 people have added BioNTech to their MarketBeat watchlist in the last 30 days. Company Ownership1.6 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, BioNTech insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $79,246,837.00 in company stock.Percentage Held by Insiders19.20% of the stock of BioNTech is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions15.52% of the stock of BioNTech is held by institutions.Read more about BioNTech's insider trading history. Receive BNTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BioNTech and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BNTX Stock News HeadlinesModerna's Rally May Have Run Out of Steam. Here's What to Watch NextOctober 26 at 4:01 PM | investopedia.comBioNTech and DualityBio announce topline results of the DYNASTY-Breast02 global phase 3 clinical trialOctober 26 at 9:29 AM | msn.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 27 at 1:00 AM | Weiss Ratings (Ad)Moderna Tumbles 7% as Cancer Vaccine Selloff Deepens; BioNTech Falls 3%, Pfizer Holds SteadyOctober 26 at 9:14 AM | 247wallst.comBioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 27,000 Shares of Company StockOctober 10, 2026 | insidertrades.comBioNTech (NASDAQ:BNTX) CEO Sells 24,000 Shares of Company StockOctober 8, 2026 | insidertrades.comBioNTech (NASDAQ:BNTX) CEO Sells $2,033,010.00 in StockOctober 7, 2026 | insidertrades.comBioNTech (NASDAQ:BNTX) CEO Ugur Sahin Sells 17,000 Shares of Company StockOctober 3, 2026 | insidertrades.comSee More Headlines BNTX Stock Analysis - Frequently Asked Questions How have BNTX shares performed this year? BioNTech's stock was trading at $95.20 at the start of the year. Since then, BNTX shares have decreased by 10.3% and is now trading at $85.3710. How were BioNTech's earnings last quarter? BioNTech SE Sponsored ADR (NASDAQ:BNTX) issued its quarterly earnings data on Tuesday, August, 4th. The company reported ($2.53) earnings per share for the quarter, missing the consensus estimate of ($2.40) by $0.14. The company's revenue for the quarter was down 59.5% on a year-over-year basis. Read the conference call transcript. How will BioNTech's stock buyback program work? BioNTech's board initiated a stock buyback program on Thursday, May 7th 2026, which authorizes the company to buy back $1 billion in shares, according to EventVestor. This means that the company could repurchase up to 4.2% of its shares through open market purchases. Shares buyback programs are often an indication that the company's board believes its shares are undervalued. Does BioNTech have any subsidiaries? The following companies are subsidiaries of BioNTech: Apta IT, BioNTech Austria Beteiligungen GmbH, BioNTech Business Services, BioNTech Cell & Gene Therapies, BioNTech Diagnostics, BioNTech Innovative Manufacturing Services, BioNTech Protein Therapeutics, and others. When did BioNTech IPO? BioNTech (BNTX) raised $155 million in an IPO on Thursday, October 10th 2019. The company issued 10,000,000 shares at $15.00-$16.00 per share. J.P. Morgan, BofA Merrill Lynch, UBS Investment Bank and SVB Leerink acted as the underwriters for the IPO and Canaccord Genuity, Bryan, Garnier, Berenberg, Wolfe Capital Markets and Advisory, Kempen and Mirae Asset Securities were co-managers. Who are BioNTech's major shareholders? BioNTech's top institutional investors include Assenagon Asset Management S.A. (0.30%), Slow Capital Inc. (0.02%), Sivik Global Healthcare LLC (0.01%) and Crocodile Capital Partners GmbH (0.01%). Insiders that own company stock include Sierk Poetting and Ugur Sahin. View institutional ownership trends. How do I buy shares of BioNTech? Shares of BNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of BioNTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that BioNTech investors own include Moderna (MRNA), NVIDIA (NVDA), Tesla (TSLA), Pfizer (PFE), Advanced Micro Devices (AMD), Novavax (NVAX) and NIO (NIO). Company Calendar Last Earnings8/04/2026Today10/27/2026Next Earnings (Estimated)11/03/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2w+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 For the last 2 weeks, BNTX's financial health has been in the Yellow zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:BNTX CIK1776985 Webwww.biontech.com Phone49-61-31908-40Fax49-6131-908-4390Employees7,807Year Founded2008Price Target and Rating Average Price Target for BioNTech$125.80 High Price Target$155.00 Low Price Target$94.00 Potential Upside/Downside+45.2%Consensus RatingModerate Buy Rating Score (0-4)2.68 Research Coverage19 Analysts Profitability EPS (Trailing Twelve Months)($7.83) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$1.29 billion Net Margins-63.54% Pretax Margin-62.27% Return on Equity-6.86% Return on Assets-6.00% Debt Debt-to-Equity Ratio0.01 Current Ratio7.85 Quick Ratio7.80 Sales & Book Value Annual Sales$3.25 billion Price / Sales6.75 Cash Flow$1.31 per share Price / Cash Flow66.00 Book Value$96.59 per share Price / Book0.90Miscellaneous Outstanding Shares252,880,000Free Float204,330,000Market Cap$21.92 billion OptionableOptionable Beta1.25 Social Links 7 Blue-Chip Stocks to Add To Your Forever PortfolioA strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership. This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.Get This Free Report This page (NASDAQ:BNTX) was last updated on 10/27/2026 by MarketBeat.com Staff. From Our PartnersTrump’s issues shocking Executive Order on U.S. DollarThree days into his second term, President Trump signed Executive Order 14178 a move the press barely covered....Banyan Hill Publishing | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | Sponsored80 Days Until America's Rare Earth Supply Chain ShiftChina controls more than 90% of global rare earth alloy production, leverage it is using to restrict exports t...The Tomorrow Investor | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredMy next big call (under $1)17,556% on KDA. 3,900% on PRE. 2,650% on OCEAN. Every single one of these was recommended to our community bef...Crypto 101 Media | SponsoredHe turned $12K into $1.65M without touching Apple or TeslaTim Sykes turned $12,415 in gift money into more than $1.65 million before graduating college, without trading...Tim Sykes | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredTwo charts tell you the future…Gold miners are posting record cash flows, outperforming every other sector, yet mining still makes up just 1%...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioNTech SE Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share BioNTech With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
